MBRX

Conviction 8HealthcareScan · Tue, Sep 8, 2026

Shooting star

MBRX$0.7586+6.86%

ResistanceSupportVol 14Insider buy

Vol MA14 605.7K

Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8

Moleculin Biotech, Inc.PHARMACEUTICAL PREPARATIONSwww.moleculin.com ↗

Price0.7586

Change+6.86%

Gap+4.01%

Rel volume0.54×

Avg volume757.86K

Avg $ vol461.39K

SMA 200.6207

SMA 501.34

SMA 2002.67

Price vs 50-43.53%

Price vs 200-71.64%

MA stackbearish

50/200 cross—

Supertrenddown · 0.9102

RSI (14)44

MACD hist0.08

MACD cross—

Stoch %K / %D83 / 79

ADX (14)33

+DI / −DI24 / 27

RSI divergence—

MACD divergence—

ATR %+13.36%

ADR %11.03%

52w high7.71

52w low0.2727

From 52w high-90.16%

Above 52w low+178.18%

New 52w highNo

SqueezeOff

Bollinger width43.31%

%B1.01

Donchian pos89.38%

Donchian high0.8000

Donchian low0.4100

AVWAP (52w high)1.93

vs AVWAP high-60.60%

AVWAP (52w low)0.4826

vs AVWAP low+57.19%

OBV trendUp

Chaikin MF (20)0.07

Today vs 20d0.54×

Avg vol (14d)605.7K

Avg vol (20d)757.86K

Avg $ vol (20d)461.39K

Market cap14.78M

RS 3m (vs SPY)-74.85%

RS 6m (vs SPY)-80.42%

RS line new highNo

Trend template2/8

Technical rank22.7

1 week+17.67%

1 month+85.25%

3 months-69.29%

6 months-61.30%

1 year+102.29%

YTD-79.04%

P/E-0.44

P/B1.28

P/S—

P/FCF-0.65

EPS-0.5900

Div yield—

ROE-289.63%

ROA-159.15%

Debt/Eq—

Current0.94

EV/EBITDA-0.30

Gross margin—

Net margin—

Rev growth—

EPS growth-28.84%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value7.51M

Revenue0

Net income-7.63M

Gross profit—

Free cash flow-22.73M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out5.34M

Employees17

ListedThu, Jun 2, 2016

Free float4.93M

Float %92.4%

Short interest316.39K

Days to cover0.1d

Short volume40.4%

Squeeze score14 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$1.40 vs −$1.55

Last surprise+9.7% beat

Setup gradeD

Conviction8 / 100

Pattern quality—

Tech rank22.7 / 100

Group rank96 / 100 · Leading

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmShooting star

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in MBRX

All disclosures →

No recent disclosed trades by Congress in MBRX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in MBRX · 6 buys

Insider	Side	Shares	Value	Traded	Filed
Foster Jonathan P. Chief Financial Officer · Common Stock · 2026-08-03	Buy	293.33K	—	2026-08-03	2026-08-05
Foster Jonathan P. Chief Financial Officer · Series I Warrants · 2026-08-03	Buy	880K	—	2026-08-03	2026-08-05
KLEMP WALTER V CEO and President · Common Stock · 2026-08-03	Buy	533.33K	—	2026-08-03	2026-08-05
KLEMP WALTER V CEO and President · Series I Warrants · 2026-08-03	Grant	1.6M	—	2026-08-03	2026-08-05
PICKER DONALD H Chief Science Officer · Common Stock · 2026-08-03	Buy	173.33K	—	2026-08-03	2026-08-05
PICKER DONALD H Chief Science Officer · Series I Warrants · 2026-08-03	Buy	520K	—	2026-08-03	2026-08-05

SEC filings

EDGAR filings in MBRX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.